Wedbush reaffirmed their outperform rating on shares of Stemline Therapeutics Inc (NASDAQ:STML) in a research note issued to investors on Saturday morning. The brokerage currently has a $11.00 price objective on the biopharmaceutical company’s stock.
A number of other research firms have also issued reports on STML. Roth Capital restated a buy rating and issued a $32.00 target price on shares of Stemline Therapeutics in a report on Wednesday, December 7th. HC Wainwright reaffirmed a buy rating and issued a $34.00 price target on shares of Stemline Therapeutics in a research note on Monday, December 12th. Jefferies Group LLC set a $23.00 price target on shares of Stemline Therapeutics and gave the stock a buy rating in a research note on Sunday, December 4th. Zacks Investment Research downgraded shares of Stemline Therapeutics from a hold rating to a sell rating in a research note on Wednesday, January 18th. Finally, Ladenburg Thalmann Financial Services set a $41.00 price target on shares of Stemline Therapeutics and gave the stock a buy rating in a research note on Monday, March 20th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $24.33.
Shares of Stemline Therapeutics (NASDAQ:STML) traded down 2.81% on Friday, hitting $8.65. The stock had a trading volume of 96,674 shares. Stemline Therapeutics has a one year low of $4.79 and a one year high of $14.60. The company’s market cap is $155.28 million. The firm’s 50-day moving average is $8.70 and its 200-day moving average is $10.40.
ILLEGAL ACTIVITY NOTICE: “Stemline Therapeutics’ (STML) Outperform Rating Reaffirmed at Wedbush” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.com-unik.info/2017/04/21/wedbush-reiterates-outperform-rating-for-stemline-therapeutics-inc-stml-2-updated-updated.html.
In other news, CEO Ivan Bergstein sold 17,980 shares of the firm’s stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $6.99, for a total value of $125,680.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David Gionco sold 6,486 shares of the firm’s stock in a transaction dated Tuesday, February 28th. The shares were sold at an average price of $6.99, for a total value of $45,337.14. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,653 shares of company stock worth $364,803. 16.70% of the stock is currently owned by company insiders.
Several large investors have recently modified their holdings of the stock. Perceptive Advisors LLC bought a new stake in Stemline Therapeutics during the fourth quarter valued at $115,000. Nationwide Fund Advisors boosted its stake in Stemline Therapeutics by 7.8% in the first quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 858 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 11,300 shares during the last quarter. Oak Ridge Investments LLC boosted its stake in Stemline Therapeutics by 26.3% in the third quarter. Oak Ridge Investments LLC now owns 12,796 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 2,663 shares during the last quarter. Finally, State Treasurer State of Michigan bought a new stake in Stemline Therapeutics during the third quarter valued at $217,000. 37.76% of the stock is currently owned by institutional investors.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
What are top analysts saying about Stemline Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stemline Therapeutics Inc and related companies.